CL2023001446A1 - Formas cristalinas de 4-amino-n-[4-(metoximetil)fenil]-7-(1- metilciclopropil)-6-(3-morfolinoprop-1-in-1-il)-7h-pirrolo [2,3-d]pirimidin-5-carboxamida - Google Patents

Formas cristalinas de 4-amino-n-[4-(metoximetil)fenil]-7-(1- metilciclopropil)-6-(3-morfolinoprop-1-in-1-il)-7h-pirrolo [2,3-d]pirimidin-5-carboxamida

Info

Publication number
CL2023001446A1
CL2023001446A1 CL2023001446A CL2023001446A CL2023001446A1 CL 2023001446 A1 CL2023001446 A1 CL 2023001446A1 CL 2023001446 A CL2023001446 A CL 2023001446A CL 2023001446 A CL2023001446 A CL 2023001446A CL 2023001446 A1 CL2023001446 A1 CL 2023001446A1
Authority
CL
Chile
Prior art keywords
morpholinoprop
methylcyclopropyl
pyrrolo
methoxymethyl
carboxamide
Prior art date
Application number
CL2023001446A
Other languages
English (en)
Inventor
Frasca Gionata
Fumagalli Tiziano
Luca Giaffreda Stefano
Modena Enrico
Ianni Cristina
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of CL2023001446A1 publication Critical patent/CL2023001446A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan diversas formas cristalinas de 4-amino-N-4-(metoximetil)fenil-7 -(1-metilciclopropil)-6-(3-morfolinoprop-1-in-1-il)-7H-pirrolo 2,3-d pirimidin-5 5-carboxamida (vepafestinib), métodos de producción de las mismas, y métodos de uso de las mismas para la inhibición de RET.
CL2023001446A 2020-11-20 2023-05-18 Formas cristalinas de 4-amino-n-[4-(metoximetil)fenil]-7-(1- metilciclopropil)-6-(3-morfolinoprop-1-in-1-il)-7h-pirrolo [2,3-d]pirimidin-5-carboxamida CL2023001446A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063116191P 2020-11-20 2020-11-20

Publications (1)

Publication Number Publication Date
CL2023001446A1 true CL2023001446A1 (es) 2023-12-29

Family

ID=78770633

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001446A CL2023001446A1 (es) 2020-11-20 2023-05-18 Formas cristalinas de 4-amino-n-[4-(metoximetil)fenil]-7-(1- metilciclopropil)-6-(3-morfolinoprop-1-in-1-il)-7h-pirrolo [2,3-d]pirimidin-5-carboxamida

Country Status (13)

Country Link
US (1) US20240010653A1 (es)
EP (1) EP4247814A1 (es)
JP (1) JP2023552305A (es)
KR (1) KR20230110547A (es)
CN (1) CN116724041A (es)
AR (1) AR124092A1 (es)
AU (1) AU2021380910A1 (es)
CA (1) CA3201274A1 (es)
CL (1) CL2023001446A1 (es)
IL (1) IL302438A (es)
MX (1) MX2023005909A (es)
TW (1) TW202237608A (es)
WO (1) WO2022106514A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3269370T (pt) 2016-02-23 2020-03-05 Taiho Pharmaceutical Co Ltd Novo composto de pirimidina condensada ou sal do mesmo

Also Published As

Publication number Publication date
WO2022106514A1 (en) 2022-05-27
KR20230110547A (ko) 2023-07-24
CN116724041A (zh) 2023-09-08
AU2021380910A1 (en) 2023-05-25
IL302438A (en) 2023-06-01
AR124092A1 (es) 2023-02-15
TW202237608A (zh) 2022-10-01
CA3201274A1 (en) 2022-05-27
MX2023005909A (es) 2023-05-26
US20240010653A1 (en) 2024-01-11
JP2023552305A (ja) 2023-12-15
EP4247814A1 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
UY37781A (es) Proceso para la preparación de pirazolo[1,5-a] pirimidinas y sales de las mismas
CL2011002956A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak1); composicion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune, cancer, trastorno mieloproliferativo, una enfermedad inflamatoria o rechazo de trasplante de organos.
UY28514A1 (es) Nuevos compuestos
DK3800189T3 (da) Fremstilling af (s)-n-(5-((r)-2-(2,5-difluorphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
CR9840A (es) Inhibidores de la pde y combinaciones de los mismos para el tratamiento de trastornos urologicos
ECSP109937A (es) Pirimidil ciclopentanos como inhibidores de la proteína quinasa akt.
EA200500721A1 (ru) Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
ITMI20052171A1 (it) Composti e-amminocarbonil bicicloepten pirimidindiamminici stereoisomericamente arricchiti e loro uso
DOP2005000013A (es) Formas polimórficas de 4,5,6,7-tetrahidroisoxazolo[5,4-c]piridin-3-ol
UY30057A1 (es) Pirimidinas sustituidas con sulfoximinas, procesos para su producción y uso de las mismas como fármacos
UY28501A1 (es) Compuestos químicos
SV2008002542A (es) Formas solidas cristalinas de tigeciclina y metodos para preparar los mismos ref. 01142.0379-00267 (am101946sv)
ECSP077276A (es) Compuestos de aminoheteroarilo enantiomericamente puroscomo inhibidores de proteina quinasa
UY36176A (es) Formas cristalinas de (2r, 5s, 13ar)-8-hidroxi-7,9- dioxo- n-(2,4,6 - trifluorobencil)-2,3,4,5,7,9,13,13a -octahidro -2,5- metanopirido[1?,2?,4,5]pirazino[2,1-b][1,3]oxazapina- 10-carboxamida
CL2012000917A1 (es) Compuestos derivados de pirazolo [3,4-d] pirimidina, inhibidores btk; y uso en el tratamiento del cancer, enfermedades autoinmune, mastocitosis,osteoporosis,entre otras.
MX2020003375A (es) Sales de inhibidores de macrofagos asociados a tumores (tam).
HN2005029978A (es) Formulaciones
CL2021002656A1 (es) Compuestos de pirrolotriazina, inhibidores selectivos de proteínas quinasas kit y pdgfralfa; composición y uso.
UY28670A1 (es) Arilpirazoles sustituidos
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
PE20110584A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIMIDINA COMO INHIBIDORES DE MET, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU PROCEDIMIENTO DE PREPARACION
CO2023007677A2 (es) Derivados de pyrazolo[1,5-a]pirazina como inhibidores de la btk
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
ECSP21021189A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
CL2023001446A1 (es) Formas cristalinas de 4-amino-n-[4-(metoximetil)fenil]-7-(1- metilciclopropil)-6-(3-morfolinoprop-1-in-1-il)-7h-pirrolo [2,3-d]pirimidin-5-carboxamida